Literature DB >> 3092310

Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity.

R I Schiff.   

Abstract

The half-life (t1/2) and clearance of IgG and three antibodies--to tetanus, pneumococcus type 3, and pneumococcus type 7--were evaluated in 38 patients who participated in a multicenter, double-blind, crossover study comparing two immunoglobulin G intravenous preparations, IGIV pH 6.8 and the new IGIV pH 4.25. IgG metabolism was evaluated after the sixth infusion by measuring the decline in concentration of IgG and specific antibody. The t1/2 values of IgG varied greatly, but the mean values of 32 and 37 days are comparable to those determined in previous studies with use of radiolabeled IgG and are longer than those reported in normal volunteers. The t1/2 values for specific antibodies, especially those to tetanus, tended to be shorter than those for IgG. The clearance of IgG and antibodies also varied widely, but even though there was some relationship between the clearance and t1/2 in individual patients, the poor correlation (R2 less than .5) suggested that other factors, such as redistribution or loss of damaged molecules, are as important as the catabolic rate. Thus, clearance may be a more reliable parameter than t1/2 in evaluating the metabolism of IgG.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092310     DOI: 10.1093/clinids/8.supplement_4.s449

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  10 in total

1.  IVIg attenuates TLR-9 activation in B cells from SLE patients.

Authors:  Aharon Kessel; Regina Peri; Tharwat Haj; Ayelet Snir; Gleb Slobodin; Edmond Sabo; Itzhak Rosner; Yehuda Shoenfeld; Elias Toubi
Journal:  J Clin Immunol       Date:  2010-10-05       Impact factor: 8.317

Review 2.  Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors.

Authors:  Devesh Mewar; Anthony G Wilson
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 3.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

4.  Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin.

Authors:  M Toyoda; X Zhang; A Petrosian; O A Galera; S J Wang; S C Jordan
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

5.  Half-life of the maternal IgG1 allotype in infants.

Authors:  H Sarvas; I Seppälä; S Kurikka; R Siegberg; O Mäkelä
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

6.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors:  R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

7.  Transplacental transmission of serotype-specific pneumococcal antibodies in a Brazilian population.

Authors:  B T Carvalho; M M Carneiro-Sampaio; D Solé; C Naspitz; L E Leiva; R U Sorensen
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

Review 8.  Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.

Authors:  B Pirofsky; D M Kinzey
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

9.  A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma.

Authors:  Melvin Berger
Journal:  J Clin Immunol       Date:  2007-10-02       Impact factor: 8.317

10.  Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases.

Authors:  Melvin Berger; Paul J Pinciaro
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.